clinical trial · NCT06873516
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
Chronic Spontaneous UrticariaEVO756EVO756EVO756Placebo control
brief summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
started
Mar 20, 2025
primary completion
May 1, 2026
completion
May 1, 2026
last updated
Apr 9, 2026
official title
A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol